Literature DB >> 27807633

[Pancreatic acinar neoplasms : Comparative molecular characterization].

F Bergmann1.   

Abstract

Pancreatic acinar cell carcinomas are biologically aggressive neoplasms for which treatment options are very limited. The molecular mechanisms of tumor initiation and progression are largely not understood and precursor lesions have not yet been identified. In this study, pancreatic acinar cell carcinomas were cytogenetically characterized as well as by molecular and immunohistochemical analyses. Corresponding investigations were carried out on pancreatic ductal adenocarcinomas and pancreatic neuroendocrine neoplasms augmented by functional analyses. We show that pancreatic acinar cell carcinomas display a microsatellite stable, chromosomal unstable genotype, characterized by recurrent chromosomal imbalances that clearly discriminate them from pancreatic ductal adenocarcinomas and neuroendocrine neoplasms. Based on findings obtained from comparative genomic hybridization, candidate genes could be identified, such as deleted in colorectal cancer (DCC) and c-MYC. Furthermore, several therapeutic targets were identified in acinar cell carcinomas and other pancreatic neoplasms, including epidermal growth factor receptor (EGFR), L1 cell adhesion molecule (L1CAM) and heat shock protein 90 (HSP90). Moreover, L1CAM was shown to play a significant role in the tumorigenesis of pancreatic ductal adenocarcinoma. Functional analyses in cell lines derived from pancreatic neuroendocrine neoplasms revealed promising anti-tumorigenic effects using EGFR and HSP90 inhibitors affecting the cell cycle and in the case of HSP90, regulating several other oncogenes. Finally, based on mutational analyses of mitochondrial DNA, molecular evidence is provided that acinar cell cystadenomas (or better cystic acinar transformation) represent non-clonal lesions, suggesting an inflammatory reactive non-neoplastic nature.

Entities:  

Keywords:  Acinar cell carcinoma; Genetics; Neoplasms; Pancreas; Targeted therapy

Mesh:

Substances:

Year:  2016        PMID: 27807633     DOI: 10.1007/s00292-016-0235-z

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  19 in total

1.  V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.

Authors:  O M Grbovic; A D Basso; A Sawai; Q Ye; P Friedlander; D Solit; N Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-21       Impact factor: 11.205

2.  Acinar cell carcinoma of the pancreas: is resection justified even in limited metastatic disease?

Authors:  Werner Hartwig; Maike Denneberg; Frank Bergmann; Thilo Hackert; Ulf Hinz; Oliver Strobel; Markus W Büchler; Jens Werner
Journal:  Am J Surg       Date:  2011-03-27       Impact factor: 2.565

3.  Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma.

Authors:  Frank Bergmann; Frauke Wandschneider; Bence Sipos; Gerhard Moldenhauer; Bodo Schniewind; Thilo Welsch; Peter Schirrmacher; Günter Klöppel; Peter Altevogt; Heiner Schäfer; Susanne Sebens Müerköster
Journal:  Oncol Rep       Date:  2010-10       Impact factor: 3.906

4.  High HSP90 expression is associated with decreased survival in breast cancer.

Authors:  Elah Pick; Yuval Kluger; Jennifer M Giltnane; Christopher Moeder; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

Review 5.  Targeting the dynamic HSP90 complex in cancer.

Authors:  Jane Trepel; Mehdi Mollapour; Giuseppe Giaccone; Len Neckers
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

6.  Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases.

Authors:  Frank Bergmann; Sebastian Aulmann; Bence Sipos; Matthias Kloor; Anja von Heydebreck; Johannes Schweipert; Andreas Harjung; Philipp Mayer; Werner Hartwig; Gerhard Moldenhauer; David Capper; Gerhard Dyckhoff; Kolja Freier; Esther Herpel; Anja Schleider; Peter Schirmacher; Gunhild Mechtersheimer; Günter Klöppel; Hendrik Bläker
Journal:  Virchows Arch       Date:  2014-10-09       Impact factor: 4.064

7.  Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.

Authors:  Yuchen Jiao; Raluca Yonescu; G Johan A Offerhaus; David S Klimstra; Anirban Maitra; James R Eshleman; James G Herman; Weijie Poh; Lorraine Pelosof; Christopher L Wolfgang; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos; Laura D Wood
Journal:  J Pathol       Date:  2014-03       Impact factor: 7.996

8.  Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40.

Authors:  F Bergmann; S Aulmann; M N Wente; R Penzel; I Esposito; J Kleeff; H Friess; P Schirmacher
Journal:  J Clin Pathol       Date:  2006-02-23       Impact factor: 3.411

9.  Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer.

Authors:  Claudia Geismann; Mascha Morscheck; Dorothee Koch; Frank Bergmann; Hendrik Ungefroren; Alexander Arlt; Ming-Sound Tsao; Max G Bachem; Peter Altevogt; Bence Sipos; Ulrich R Fölsch; Heiner Schäfer; Susanne Sebens Müerköster
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

10.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.